Keith Barnett, DrPH, MS, MBA

Vice President, Clinical Operations

19 years of biopharmaceutical industry experience in Global Clinical Operations leadership spanning multiple therapeutic areas, including oncology, cardiovascular, women’s health, and radiopharmaceuticals. He previously served as Head of Clinical Operations at Pandion Therapeutics, acquired by Merck in 2021; Jounce Therapeutics, and Fusion Pharmaceuticals, acquired by AstraZeneca in 2024. Over the course of his career, he has led global clinical programs, supported multiple NDA submissions and approvals, and contributed to the FDA approval of Vyleesi at Palatin Technologies—the first on-demand treatment for female sexual dysfunction. He holds a Doctor of Public Health degree from Indiana University and is passionate about building high-performing teams that deliver meaningful therapies to patients.